William Blair Weighs in on Upstream Bio Q4 Earnings

Upstream Bio, Inc. (NASDAQ:UPB) – William Blair issued their Q4 2024 earnings per share (EPS) estimates for shares of Upstream Bio in a report issued on Tuesday, November 5th. William Blair analyst M. Phipps expects that the company will post earnings of ($0.42) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Upstream Bio’s FY2025 earnings at ($2.36) EPS, FY2026 earnings at ($2.64) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($2.26) EPS.

UPB has been the topic of a number of other research reports. Piper Sandler assumed coverage on Upstream Bio in a report on Tuesday. They issued an “overweight” rating and a $75.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on shares of Upstream Bio in a research report on Tuesday. They issued an “overweight” rating and a $38.00 target price for the company. Finally, TD Cowen started coverage on shares of Upstream Bio in a research report on Tuesday. They set a “buy” rating on the stock.

Upstream Bio Stock Up 1.7 %

Shares of NASDAQ:UPB opened at $27.02 on Thursday. Upstream Bio has a 1 year low of $20.74 and a 1 year high of $29.46.

Insider Buying and Selling at Upstream Bio

In other news, Director Erez Chimovits acquired 825,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was purchased at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the acquisition, the director now owns 4,554,873 shares of the company’s stock, valued at $77,432,841. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Upstream Bio news, major shareholder Ai Upstream Llc bought 1,175,000 shares of Upstream Bio stock in a transaction on Tuesday, October 15th. The shares were bought at an average price of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the transaction, the insider now directly owns 1,175,000 shares of the company’s stock, valued at $19,975,000. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Erez Chimovits purchased 825,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $14,025,000.00. Following the purchase, the director now owns 4,554,873 shares in the company, valued at approximately $77,432,841. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.